NCT05273567View on ClinicalTrials.gov

A Trial of Guanfacine-er for Cannabis Use Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions
Cannabis Use
Interventions
DRUG

guanfacine-ER

guanfacine-er dispensed daily, starting at 1mg and increasing to 4mg/day or the maximum tolerated dose.

OTHER

Placebo

placebo will be dispensed similar to the active arm.

Trial Locations (1)

10017

STARS Clinic at Columbia and NYSPI Department of Psychiatry, New York

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

New York State Psychiatric Institute

OTHER